Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision Therapy

LEADER Trial Will Use Results from Foundation Medicine’s Comprehensive Genomic Profiling Tests to Screen for Actionable Driver Mutations to Inform Trial Enrollment and Targeted Therapy Options for Patients

New “Trial in Progress” Abstract at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Details LEADER’s Primary Objective to Determine the Proportion of Patients Possessing Actionable Oncogenic Drivers to Enable Treatment Decisions

Excerpt from the Press Release:

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced its participation in a neoadjuvant screening trial in partnership with the Lung Cancer Research Foundation (LCRF) and Lung Cancer Mutation Consortium (LCMC). This screening trial, entitled “LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer” (LEADER), is the fourth study conducted through the LCMC and is a collaborative effort involving numerous academic study sites and pharmaceutical supporters. Foundation Medicine will be the sole provider of comprehensive genomic profiling (CGP) in the LEADER trial, which will utilize both of Foundation Medicine’s FDA-approved CGP tests: the tissue-based FoundationOne^®CDx and the blood-based FoundationOne^®Liquid CDx.

The LEADER trial is utilizing an umbrella trial design to screen for 11 actionable driver mutations in 1,000 patients with high-risk, resectable non-small cell lung cancer (NSCLC). These patients are candidates for neoadjuvant therapy, which is treatment given as a first step to shrink a tumor before the main treatment, often surgery. By identifying patients with biomarker-positive tumors for enrollment to several matched therapeutic trials, the LEADER trial aims to develop essential data that can be used to support oncologists in their personalized treatment planning for cancer patients prior to such patients undergoing surgery.

“The neoadjuvant setting is a rapidly evolving space for the development of precision treatment options in lung cancer. Enabling trials in this setting will continue to help us understand the impact of targeted therapies in the curative treatment of NSCLC,” says Dr. Geoff Oxnard, Foundation Medicine’s VP, Head of Clinical Development. “At Foundation Medicine, we are committed to being an engaged collaborator in the pivotal research needed to shape the future of cancer care for patients at all stages, so that patients can get on the right therapy at the right time for their specific cancer.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release